Biomarker discovery in lung cancer - Promises and challenges of clinical proteomics

Ajit Bharti, Patrick Chi-Chung Ma, Ravi Salgia

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Lung cancer is a devastating illness with an overall poor prognosis. To effectively address this disease, early detection and novel therapeutics are required. Early detection of lung cancer is challenging, in part because of the lack of adequate tumor biomarkers. The goal of this review is to summarize the knowledge of current biomarkers in lung cancer, with a focus on important serum biomarkers. The current knowledge on the known serum cytokines and tumor biomarkers of lung cancer will be presented. Emerging trends and new findings in the search for novel diagnostic and therapeutic tumor biomarkers using proteomics technologies and platforms are emphasized, including recent advances in mass spectrometry to facilitate tumor biomarker discovery program in lung cancer. It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication, and finally the treatment of lung cancer with potential novel molecularly targeted therapeutics.

Original languageEnglish (US)
Pages (from-to)451-466
Number of pages16
JournalMass Spectrometry Reviews
Volume26
Issue number3
DOIs
StatePublished - May 1 2007

Fingerprint

biomarkers
Biomarkers
Tumor Biomarkers
Proteomics
lungs
Lung Neoplasms
cancer
tumors
serums
platforms
Technology
Mass spectrometry
prognosis
Cytokines
Serum
Early Detection of Cancer
Early Diagnosis
emerging
Mass Spectrometry
mass spectroscopy

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Condensed Matter Physics
  • Biochemistry, Genetics and Molecular Biology(all)
  • Spectroscopy

Cite this

@article{04da53bbad424e64b24ffb84e39af8fd,
title = "Biomarker discovery in lung cancer - Promises and challenges of clinical proteomics",
abstract = "Lung cancer is a devastating illness with an overall poor prognosis. To effectively address this disease, early detection and novel therapeutics are required. Early detection of lung cancer is challenging, in part because of the lack of adequate tumor biomarkers. The goal of this review is to summarize the knowledge of current biomarkers in lung cancer, with a focus on important serum biomarkers. The current knowledge on the known serum cytokines and tumor biomarkers of lung cancer will be presented. Emerging trends and new findings in the search for novel diagnostic and therapeutic tumor biomarkers using proteomics technologies and platforms are emphasized, including recent advances in mass spectrometry to facilitate tumor biomarker discovery program in lung cancer. It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication, and finally the treatment of lung cancer with potential novel molecularly targeted therapeutics.",
author = "Ajit Bharti and Ma, {Patrick Chi-Chung} and Ravi Salgia",
year = "2007",
month = "5",
day = "1",
doi = "10.1002/mas.20125",
language = "English (US)",
volume = "26",
pages = "451--466",
journal = "Mass Spectrometry Reviews",
issn = "0277-7037",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

Biomarker discovery in lung cancer - Promises and challenges of clinical proteomics. / Bharti, Ajit; Ma, Patrick Chi-Chung; Salgia, Ravi.

In: Mass Spectrometry Reviews, Vol. 26, No. 3, 01.05.2007, p. 451-466.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biomarker discovery in lung cancer - Promises and challenges of clinical proteomics

AU - Bharti, Ajit

AU - Ma, Patrick Chi-Chung

AU - Salgia, Ravi

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Lung cancer is a devastating illness with an overall poor prognosis. To effectively address this disease, early detection and novel therapeutics are required. Early detection of lung cancer is challenging, in part because of the lack of adequate tumor biomarkers. The goal of this review is to summarize the knowledge of current biomarkers in lung cancer, with a focus on important serum biomarkers. The current knowledge on the known serum cytokines and tumor biomarkers of lung cancer will be presented. Emerging trends and new findings in the search for novel diagnostic and therapeutic tumor biomarkers using proteomics technologies and platforms are emphasized, including recent advances in mass spectrometry to facilitate tumor biomarker discovery program in lung cancer. It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication, and finally the treatment of lung cancer with potential novel molecularly targeted therapeutics.

AB - Lung cancer is a devastating illness with an overall poor prognosis. To effectively address this disease, early detection and novel therapeutics are required. Early detection of lung cancer is challenging, in part because of the lack of adequate tumor biomarkers. The goal of this review is to summarize the knowledge of current biomarkers in lung cancer, with a focus on important serum biomarkers. The current knowledge on the known serum cytokines and tumor biomarkers of lung cancer will be presented. Emerging trends and new findings in the search for novel diagnostic and therapeutic tumor biomarkers using proteomics technologies and platforms are emphasized, including recent advances in mass spectrometry to facilitate tumor biomarker discovery program in lung cancer. It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication, and finally the treatment of lung cancer with potential novel molecularly targeted therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=34248584690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248584690&partnerID=8YFLogxK

U2 - 10.1002/mas.20125

DO - 10.1002/mas.20125

M3 - Article

C2 - 17407130

AN - SCOPUS:34248584690

VL - 26

SP - 451

EP - 466

JO - Mass Spectrometry Reviews

JF - Mass Spectrometry Reviews

SN - 0277-7037

IS - 3

ER -